orthobiologic

BOSTON, Feb. 29, 2016 /PRNewswire/ — Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the completion of a $5.75 million funding round with Musculoskeletal Transplant Foundation, OrthoFix Holdings, Inc. and Hankey Capital, LLC. Proceeds will be used primarily to fund further development and synthesis of a potential bone graft substitute product focused first on bone regeneration in spinal fusion procedures. Steve La Neve, CEO and President of Bone Biologics, noted, “We are pleased with the

“In today’s Smart Grid market, such collaborative efforts between companies such as Tollgrade and Ambient demonstrates what is required to form best-in-class solutions that will create opportunities for faster adoption of new technologies and realization of smart grid efficiencies.”